Hyderabad based pharma giant Bharat Biotech has announced successful recruitment of 13,000 volunteers for the Phase-3 clinical trial of anti-COVID-19 vaccine COVAXIN across multiple sites in
India.
The Phase III human clinical trials of COVAXIN which began mid-November targeted to be done in 26,000 volunteers across India.
This is India’s first and only Phase III efficacy study for a COVID-19 vaccine, and the largest phase III efficacy trial ever conducted for any vaccine in India.
